FDA Clears Bioness’ New Device ‘StimRouter’ to Treat Chronic Peripheral Pain

StimRouter can change the way healthcare professionals treat chronic peripheral pain by targeting and neuromodulating the affected nerve.

The U.S. Food and Drug Administration (FDA) has cleared StimRouter, an implantable neuromodulation device designed to treat chronic, intractable pain of peripheral nerve origin from.

The device was developed by Bioness, a manufacturer of unique innovative systems for rehabilitation of impairments resulting from central nervous system disorders. The StimRouter is the only implanted device to be cleared by the FDA with a specific indication for peripheral nerve stimulation.

Fracture of Knee Cap - Causes - Symptoms - Diagnosis - Treatment - FAQs
Patella fracture is a kneecap injury that needs surgical correction. Undisplaced fracture can be healed by using a brace to keep the knee immobile.

Bioness founder Alfred Mann said that StimRouter is a disruptive technology that presents an opportunity to change the way healthcare professionals treat chronic peripheral pain by targeting and neuromodulating the affected nerve.

“The device represents a less invasive and more cost-effective treatment method when compared to commercially available pain management implanted devices,” Mann said.

Bioness President and CEO Todd Cushman said that the FDA clearance of StimRouter represents a monumental development for Bioness.

First of Its Kind Program Pioneered in Toronto Aims to Break the Chronic Pain Cycle
Researchers are pioneering a world-first transitional pain program that aims to stop pain from becoming chronic after surgery.

“The StimRouter builds on the success of our external neuromodulation systems and allows us to expand into the pain management market as well as other future applications. The positive clinical results, ease of use and a specific indication for use that targets peripheral nerve pain, make the StimRouter a unique and compelling alternative to Spinal Cord Stimulation (SCS) and opiates,” Cushman said.